Technology is not only driving medical breakthroughs – it is revolutionizing healthcare by creating new business models and transformative opportunities for innovation. Baird Capital examines this convergence of biology and technology and the current investment landscape.
Biotech has contributed to numerous recent medical advances – but can it continue to innovate in the face of pressure to lower drug prices and investor concern? Baird's senior analyst covering the sector discusses challenges, opportunities and the next potential breakthrough in this Q&A.
Strategic buyers and financial sponsors alike are targeting outsourced pharma services assets. What is commanding buyers' interest, and what lies ahead for the sector? Baird Global Investment Banking weighs in on the drivers of this strong activity.
Biotech's research and development focus is shifting toward specialty therapy areas. How can firms differentiate themselves as the sector evolves? Baird Capital discusses the changing market and its recent experience in the space.
Healthcare organizations are looking for clinical workflow and automation technology that translates data into action – and buyers are eager to acquire attractive assets. Baird Global Investment Banking investigates current investment drivers and buyer dynamics.